Orion and Propeller Health have announced that they will co-develop a custom sensor for Orion’s Easyhaler devices that will allow the inhalers to connect to Propeller’s digital inhaler monitoring platform. According to the companies, “Development of the sensor will begin in 2019, with clinical trials, possible real world evidence projects and a broader commercial rollout to follow.”
Propeller Health, which was recently acquired by ResMed, said that over 90 percent of inhaled asthma/COPD drugs are already on the platform. The company has previously announced deals with Aptar Pharma, US pharmacy benefits manager Express Scripts, GSK, Novartis, Vectura, and Boehringer Ingelheim.
Orion’ Senior VP Satu Ahomäki commented, “By connecting Easyhaler to Propeller’s digital platform, we are giving our patients and their providers a new ability to improve the user experience of Easyhaler products and help patients better adhere to the treatments,. We are thrilled to take this step to reduce the burden of asthma and COPD via a digital companion to our medicine.”
Propeller Co-Founder and CEO David Van Sickle said, “People and their physicians are eager for medicines that put digital to work to improve their treatments and quality of life. This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world.”
Read the Orion and Propeller Health press release.
